Instrument Inactif

Autres langues Neuropathix, Inc.

Actions

NPTX

US64132Q1094

Recherche biotechnologique et médicale

Autres langues

17/11	Neuropathix, Inc. announced a financing transaction
23/05/22	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
23/05/22	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
25/04/22	Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021
15/04/22	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
15/04/22	NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
15/04/22	Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt
25/03/22	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
21/03/22	Neuropathix, Inc. announced that it has received $0.15 million in funding
12/11/21	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
12/11/21	Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
28/09/21	NEUROPATHIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
12/08/21	Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board
06/08/21	NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
06/08/21	Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
20/07/21	Neuropathix : Neuropathix, Inc.
13/05/21	NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
13/05/21	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
06/05/21	Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
30/03/21	NEUROPATHIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
30/03/21	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
17/03/21	NEUROPATHIX, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
23/02/21	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
10/02/21	Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC
25/01/21	Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead